Effect of Paricalcitol Over Vessel Wall

Phase 4 Terminated 50 enrolled Effice Servicios Para la Investigacion S.L. Jaume Arnó Renal Foundation · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Timeline

Start: 2012-07
Primary completion: 2013-05
Completion: 2013-05

Outcome

Outcome not reported

Stopped: “Protocol showed to be inappropriate for the evaluation of the selected patients”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paricalcitol	Other / unclassified	1 ug	Oral

Indications

No indication recorded.